Search research articles
Contact Us
Filters
Showing results (111-120 of 215) with videos related to
Page
of 22
Sort By:
Gynecologic Oncology Reports
|
March 1, 2024
Combined aromatase, CDK4/6 and PI3K blockade using letrozole/abemaciclib/LY3023414 in endometrial cancer
Panagiotis A Konstantinopoulos, Niya Xiong, Carolyn Krasner, et al.
Journal of Alternative and Complementary Medicine (New York, N.Y.)
|
June 26, 2009
Acupuncture for chemotherapy-induced neutropenia in patients with gynecologic malignancies: a pilot randomized, sham-controlled clinical trial
Weidong Lu, Ursula A Matulonis, Anne Doherty-Gilman, et al.
Oncotarget
|
February 13, 2016
Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer
Kyle C Strickland, Brooke E Howitt, Sachet A Shukla, et al.
JAMA Oncology
|
July 17, 2015
Association of Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1
Brooke E Howitt, Sachet A Shukla, Lynette M Sholl, et al.
Molecular Cancer Therapeutics
|
January 26, 2019
Combined MEK and BCL-2/X<sub>L</sub> Inhibition Is Effective in High-Grade Serous Ovarian Cancer Patient-Derived Xenograft Models and BIM Levels Are Predictive of Responsiveness
Claudia Iavarone, Ioannis K Zervantonakis, Laura M Selfors, et al.
Future Oncology (London, England)
|
September 6, 2022
EPIK-O/ENGOT-OV61: alpelisib plus olaparib vs cytotoxic chemotherapy in high-grade serous ovarian cancer (phase III study)
Panagiotis A Konstantinopoulos, Antonio Gonzalez-Martin, Felipe Melo Cruz, et al.
Gynecologic Oncology
|
March 6, 2024
Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate, in combination with carboplatin and bevacizumab in patients with platinum-sensitive ovarian cancer
Debra L Richardson, Kathleen N Moore, Ignace Vergote, et al.
Gynecologic Oncology
|
September 14, 2023
Pilot randomized trial of an acceptance-based telehealth intervention for women with ovarian cancer and PARP inhibitor-related fatigue
Alexi A Wright, Hanneke Poort, Anna Tavormina, et al.
Cancer
|
March 19, 2021
Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive, recurrent ovarian cancer: A meta-analysis
Chee Khoon Lee, Michael L Friedlander, Angelina Tjokrowidjaja, et al.
Cancer
|
April 11, 2016
Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapy
Ursula A Matulonis, Philipp Harter, Charlie Gourley, et al.
Page
of 22
Search research articles
Search
Showing results (111-120 of 215) with videos related to
Sort By:
Page
of 22
Gynecologic Oncology Reports
|
March 1, 2024
Combined aromatase, CDK4/6 and PI3K blockade using letrozole/abemaciclib/LY3023414 in endometrial cancer
Panagiotis A Konstantinopoulos, Niya Xiong, Carolyn Krasner, et al.
Journal of Alternative and Complementary Medicine (New York, N.Y.)
|
June 26, 2009
Acupuncture for chemotherapy-induced neutropenia in patients with gynecologic malignancies: a pilot randomized, sham-controlled clinical trial
Weidong Lu, Ursula A Matulonis, Anne Doherty-Gilman, et al.
Oncotarget
|
February 13, 2016
Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer
Kyle C Strickland, Brooke E Howitt, Sachet A Shukla, et al.
JAMA Oncology
|
July 17, 2015
Association of Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1
Brooke E Howitt, Sachet A Shukla, Lynette M Sholl, et al.
Molecular Cancer Therapeutics
|
January 26, 2019
Combined MEK and BCL-2/X<sub>L</sub> Inhibition Is Effective in High-Grade Serous Ovarian Cancer Patient-Derived Xenograft Models and BIM Levels Are Predictive of Responsiveness
Claudia Iavarone, Ioannis K Zervantonakis, Laura M Selfors, et al.
Future Oncology (London, England)
|
September 6, 2022
EPIK-O/ENGOT-OV61: alpelisib plus olaparib vs cytotoxic chemotherapy in high-grade serous ovarian cancer (phase III study)
Panagiotis A Konstantinopoulos, Antonio Gonzalez-Martin, Felipe Melo Cruz, et al.
Gynecologic Oncology
|
March 6, 2024
Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate, in combination with carboplatin and bevacizumab in patients with platinum-sensitive ovarian cancer
Debra L Richardson, Kathleen N Moore, Ignace Vergote, et al.
Gynecologic Oncology
|
September 14, 2023
Pilot randomized trial of an acceptance-based telehealth intervention for women with ovarian cancer and PARP inhibitor-related fatigue
Alexi A Wright, Hanneke Poort, Anna Tavormina, et al.
Cancer
|
March 19, 2021
Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive, recurrent ovarian cancer: A meta-analysis
Chee Khoon Lee, Michael L Friedlander, Angelina Tjokrowidjaja, et al.
Cancer
|
April 11, 2016
Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapy
Ursula A Matulonis, Philipp Harter, Charlie Gourley, et al.
Page
of 22